Results 11 to 20 of about 65,576 (316)
Development of New Drugs for Autoimmune Hemolytic Anemia
Pharmaceutics, 2022 Autoimmune hemolytic anemia (AIHA) is a rare disorder characterized by the autoantibody-mediated destruction of red blood cells, and treatments for it still remain challenging.
Zhengrui Xiao, Irina Murakhovskaya
doaj +2 more sources
Bortezomib in autoimmune hemolytic anemia and beyond [PDF]
Therapeutic Advances in Hematology, 2021 Bortezomib is a first-in-class, potent, selective and reversible proteasome inhibitor approved for the treatment of multiple myeloma (MM) and relapsed/refractory mantle cell lymphoma. In these diseases, bortezomib targets plasma cells and lymphocytes reducing tumor burden.
Pasquale R. +3 more
openaire +5 more sources
The choice of new treatments in autoimmune hemolytic anemia: how to pick from the basket?
Frontiers in Immunology, 2023 Autoimmune hemolytic anemia (AIHA) is defined by increased erythrocyte turnover mediated by autoimmune mechanisms. While corticosteroids remain first-line therapy in most cases of warm-antibody AIHA, cold agglutinin disease is treated by targeting the ...
S. Berentsen, B. Fattizzo, W. Barcellini
semanticscholar +1 more source
Autoimmune hemolytic anemia: causes and consequences
Expert Review of Clinical Immunology, 2022 Introduction Autoimmune hemolytic anemia (AIHA) is classified according to the direct antiglobulin test (DAT) and thermal characteristics of the autoantibody into warm and cold forms, and in primary versus secondary depending on the presence of ...
B. Fattizzo, W. Barcellini
semanticscholar +1 more source
Autoimmune Hemolytic Anemia After mRNA COVID Vaccine
Journal of Investigative Medicine High Impact Case Reports, 2022 Discussion of the hematologic complications of vaccination for severe acute respiratory syndrome coronavirus-2 (COVID-19) has primarily focused on the development of vaccine-associated immune thrombosis with thrombocytopenia (VITT).
Z. Fatima +3 more
semanticscholar +1 more source
Journal of Thrombosis and Haemostasis, 2022 Thrombosis may complicate autoimmune hemolytic anemia (AIHA), but its predictors are still lacking, and no clear‐cut indications for anticoagulant prophylaxis are available.
B. Fattizzo +5 more
semanticscholar +1 more source
Mixed Autoimmune Hemolytic Anemia: A Systematic Review of Epidemiology, Clinical Characteristics, Therapies, and Outcomes. [PDF]
Am J HematolMixed autoimmune hemolytic anemia (AIHA) is a rare condition characterized by the presence of both warm and cold autoantibodies, often leading to severe, treatment‐resistant hemolysis. In this systematic review of 81 patients across 35 studies, the median age was 45 years with a notable female predominance.
Jacobs JW +12 more
europepmc +2 more sources
Warm autoimmune hemolytic anemia and the best treatment strategies.
Hematology. American Society of Hematology. Education Program, 2022 Warm autoimmune hemolytic anemia (wAIHA) is characterized by evidence of red blood cell (RBC) hemolysis and a direct antiglobulin test positive for IgG and sometimes complement. While varying with the extent of the compensatory increase in RBC production,
D. Kuter
semanticscholar +1 more source
Case Reports in Hematology, 2022 By this time, multiple vaccines have been approved to limit the spread of SARS-CoV-2 worldwide. These include new-generation vaccines that contain mRNA of the target organism.
Fnu Jaydev +4 more
semanticscholar +1 more source
How I treat warm autoimmune hemolytic anemia.
Blood, 2021 Warm autoimmune hemolytic anemia (wAIHA) is caused by increased erythrocyte destruction by IgG autoantibodies, with or without complement activation.
W. Barcellini, B. Fattizzo
semanticscholar +1 more source